AIM IMMUNOTECH INC

AIMNYSE AMERICAN

🏆 #3770 by market capEarnings Nov 16US Equity

$957.40▼ $58.78 (−6.14%)

Simulated price

1h—

24h▼ 6.1%

7d—

14d—

30d—

1y—

🏦Market Cap

$8M

Small Cap

📈Revenue Growth (YoY)

-35.6%

Declining

📊Gross Margin

-29.8%

Thin

💵FCF Margin

—

⚖️P/S Ratio

77.6x

Expensive

Otter Score

Weak

No chart data available for AIM.

Trading Snapshot

Day Range: $950.10 – $975.48
52-Week Range: $0.21 – $2.89
Volume: $1.95B
Avg Volume: $1.57B
Shares Outstanding: 27.7M
Next Earnings: Sep 8, 2026

Fundamentals Snapshot

Annual Revenue: $88,000
Last Q Revenue: $26,000
P/E Ratio: —
P/S Ratio: 77.6x
EPS (TTM): $-7.39
Dividend Yield: —

Why Investors Own AIM

✓High-growth profile — revenue up +13.2% YoY with expanding US Equity exposure.
✓Healthy economics — 39% gross margin and 15% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$88,000▲ +14.2% YoY

Gross Margin (TTM)

38.7%▲ +1.4% YoY

Operating Income (TTM)

$11,616▲ +14.2% YoY

Free Cash Flow (TTM)

$12,936▲ +14.2% YoY

About AIM IMMUNOTECH INC

AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.

🦦